Biocon's unit, in partnership with Carnegie Pharmaceuticals, has secured tentative approval from the USFDA for Rifaximin Tablets. This genetic anti-bacterial medication is used to reduce the risk of hepatic encephalopathy recurrence and treat irritable bowel syndrome with diarrhoea. The approval marks a significant step for the company in the pharmaceutical market.